Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. Molecular Analysis for Precision Oncology Congress 2023

The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies

Panel discussion

Date

06 Oct 2023

Session

The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies

Presenters

Dario Trapani

Authors

F. André1, W. Bordogna2, E. Garralda3, M. Jamal-Hanjani4, E. Lengline5, S. Loi6, A. Majdi7, S. Michiels8, N. Morsli9, F. Pignatti10, B. Ryll11, N. Shire12, D. Trapani13

Author affiliations

  • 1 Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 F. Hoffmann-La Roche AG, 4070 - Basel/CH
  • 3 Early Drug Development Group, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 4 Medical Oncology Dept., UCL Cancer Institute - Paul O'Gorman Building, WC1 E6JD - London/GB
  • 5 Haute Autorité de Santé (HAS), Paris/FR
  • 6 Translational Breast Cancer Genomics Lab - Research, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 7 Global Medical Affairs Oncology, Bayer Healthcare - France, 59120 - Loos/FR
  • 8 Team Oncostat, Cesp, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 9 AstraZeneca UK Ltd, CB2 1PG - Cambridge/GB
  • 10 Office Of Oncology And Haematology, European Medicines Agency - Amsterdam, 1083 HN - Amsterdam/NL
  • 11 Melanoma Dept, Melanoma Patient Network Europe MPNE, 755 97 - Uppsala/SE
  • 12 AstraZeneca USA, 20878 - Gaithersburg/US
  • 13 Medical Oncology, Università degli Studi di Milano, 20122 - Milan/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

The future of the tissue agnostic targets

Presenter: Joaquin Mateo

Session: The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies

Resources:

Slides

Webcast

Wrap-up and roadmap for actions

Presenter: Joaquin Mateo

Session: The next wave of pan-cancer clinical trials: How can we optimally run histology agnostic biomarker-driven studies

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.